Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Pituitary Disorders
•
Primary Care
When and how do you taper off cabergoline therapy for treatment of microprolactinoma?
Answer from: at Community Practice
If patient does not desire fertility and microprolactinoma is stable or smaller, cabergoline can be tapered off.
Comments
at Northwestern University Endocrinology
The dose should be gradually tapered down to 0.5 m...
12127
Sign in or Register to read more
21564
Related Questions
How do you approach mild prolactin elevations (20-80) in women with galactorrhea on nipple stimulation but regular menses and no plans for pregnancy?
Do you recommend increased screening for hypercortisolism in older patients given recent evidence that older patients do not commonly display hallmark symptoms of Cushing's Disease?
Do you recommend checking both TSI and TBII antibodies for Graves' disease diagnosis and monitoring?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
How would you manage new onset amenorrhea, diabetes insipidus and growth hormone deficiency without other pituitary deficiencies or excess in young females with MRI findings of pituitary mass and hypothalamic edema?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
How do you counsel patients on the use of compounded weight loss medications?
What is your approach to managing symptomatic primary hyperparathyroidism in the third trimester of pregnancy?
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
The dose should be gradually tapered down to 0.5 m...